Anastrozole and breast cancer risk: sorting TRT claims from oncology facts

What did @moveforwardkv actually say?

She made several distinct claims worth separating. First, she stopped taking anastrozole because she believed it "crosses the brain barrier and could lead to Alzheimer's." Second, after restarting the drug, she experienced heart palpitations and elevated blood pressure within about a week and a half. Third, she found a 2020 American Heart Association journal study linking aromatase inhibitors to increased risk of heart failure and cardiovascular mortality compared to tamoxifen. She concludes, with genuine alarm, that "some of my cancer medicine is trying to kill you." To be clear: she is not a medical professional, she stopped a prescribed cancer medication without telling her oncologist, and she is presenting a real but incomplete reading of a real study. Some of what she said has genuine clinical backing. Some of it is missing critical context that could actually harm other patients who take her experience as a template.

Does the science back this up?

Partly, yes. The study she cited is real. The reference tracks to Khosrow-Khavar et al., published in the Journal of the American College of Cardiology in 2020, which used a large population-based cohort to compare aromatase inhibitor users to tamoxifen users. It found aromatase inhibitors were associated with a higher risk of heart failure and cardiovascular mortality. That finding has been replicated in other work, including Abdel-Qadir et al. (2016, JACC) and an analysis by Foglietta et al. (2017, Oncologist). The biological rationale is real too: estrogen plays a cardioprotective role, and anastrozole suppresses estrogen dramatically. That physiological effect on the cardiovascular system is not a fringe concern.

However, here is what the study does not say: it does not say anastrozole causes acute heart palpitations within ten days of restarting a dose. Heart failure risk in these studies is a long-term population-level signal, not a mechanism that flips on in a week. Her acute symptoms almost certainly have a different explanation, possibly anxiety, withdrawal from supplements, or another variable entirely.

What did they get wrong (or right)?

She got the study citation essentially right, which is more than most TikTok health content manages. Credit where it is due. The cardiovascular risk signal for aromatase inhibitors compared to tamoxifen is a real, documented concern that oncologists and cardiologists genuinely debate.

What she got wrong is the causation framing for her immediate symptoms. Acute palpitations appearing "over the course of about a week and a half" are not consistent with the mechanism by which aromatase inhibitors affect cardiac risk in the literature. That risk accumulates over months to years of estrogen suppression, not days. Attributing rapid-onset palpitations directly to anastrozole resumption, and then quitting the drug based on that reasoning, is a leap the science does not support.

The Alzheimer's claim is more complicated. There is preliminary research suggesting estrogen has neuroprotective effects, and some animal studies have raised questions about aromatase inhibition and cognitive function. But the evidence is not strong enough to call anastrozole a direct Alzheimer's risk driver in humans. She presented that as settled fact. It is not.

Most concerning: she stopped a prescribed aromatase inhibitor without medical guidance, twice, and is now framing that decision as validated by a study. That framing could encourage other breast cancer patients to do the same, which carries real recurrence risk.

What should you actually know?

If you are on anastrozole or another aromatase inhibitor for breast cancer, the cardiovascular monitoring question is legitimate and worth raising with your oncologist. The 2020 Khosrow-Khavar study is real and has influenced how some clinicians approach cardiac monitoring in hormone receptor-positive breast cancer patients. You deserve an honest conversation about that risk-benefit tradeoff.

But stopping anastrozole unilaterally because of a TikTok video, or because of self-diagnosed heart palpitations, is not a safe response to that legitimate concern. Aromatase inhibitors reduce breast cancer recurrence risk significantly in hormone receptor-positive disease. That benefit is not trivial. The comparison in the cardiovascular studies is typically against tamoxifen, another active treatment, not against nothing. The question is not "anastrozole vs. no drug." It is "anastrozole vs. tamoxifen," with different side effect profiles on both sides.

If you are experiencing palpitations or blood pressure changes while on any hormone-related therapy, report them to your prescriber. Do not stop a cancer medication based on symptom self-diagnosis and a Google search, even a well-intentioned one.